Biocon Limited appoints Shreehas Tambe as CEO & Managing Director, effective April 1, 2026, following board and NRC approval.
Kedar Upadhye named CFO; outgoing CEO Siddharth Mittal transitions to another leadership role within the Biocon Group.
The appointment coincides with full integration of Biocon Biologics as a wholly owned subsidiary, creating a unified biopharma platform.
Biocon Biologics is valued at USD 5.5 billion and ranks among the world's top five biosimilar companies by revenue.